Related Experiment Video
Updated: Mar 1, 2026
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model
Kara K Rossfeld1, Steven E Justiniano2, Haiming Ding3
1Department of Surgery, Ohio State University-Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Ohio State University, Columbus, Ohio 43210.
Context:
The primary and definitive treatment of medullary thyroid cancer (MTC) is surgical resection. Recurrent or residual disease is typically a result of incomplete surgical removal.
Objective:
Our objective is to develop a compound that assists in intraoperative visualization of cancer, which would have the potential to improve surgical cure rates and outcomes.
Results:
We report the biological characterization of Compound-17, which is labeled with IRdye800, allowing fluorescent visualization of MTC mouse models. We found that the agent has high affinity for two human MTC cell lines (TT and MZ-CRC1) in vitro and in vivo. We further tested the affinity of the compound in a newly developed MTC orthotopic xenograft model and found that Compound-17 produces fluorescent signals within MTC-derived orthotopic xenografts in comparison with a sequence-jumbled control compound and surrounding normal tissues.
Conclusions:
Compound-17 is a unique and effective molecule for MTC identification that may have therapeutic potential.
Insights
Compound-17, a novel fluorescent agent, effectively visualizes medullary thyroid cancer (MTC) in preclinical models. This imaging compound shows promise for improving surgical detection and outcomes in MTC patients.
Area of Science:
- Oncology
- Medical Imaging
- Drug Development
Background:
- Medullary thyroid cancer (MTC) treatment relies on surgical resection.
- Incomplete tumor removal leads to recurrent or residual disease.
Purpose of the Study:
- To develop an imaging agent for intraoperative visualization of MTC.
- To improve surgical cure rates and patient outcomes for MTC.
Main Methods:
- Biological characterization of Compound-17, labeled with IRdye800.
- In vitro and in vivo testing of Compound-17 affinity in MTC cell lines.
- Evaluation in a novel MTC orthotopic xenograft model.
Main Results:
- Compound-17 demonstrated high affinity for human MTC cell lines (TT and MZ-CRC1).
- Fluorescent signals were detected in MTC orthotopic xenografts using Compound-17.
- Compound-17 showed specific signal in tumors compared to control and normal tissues.
Conclusions:
- Compound-17 is an effective molecule for identifying MTC.
- The agent facilitates fluorescent visualization of MTC in preclinical models.
- Compound-17 holds potential for therapeutic applications in MTC management.
